Keyword: Nichi-Iko Pharmaceutical

Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.

A third carcinogen was found in sartan drugs; China unveiled final rules for a Nasdaq-style board; Philippines preps to indict Sanofi officials.

Japan’s Nichi-Iko Pharmaceutical and its U.S. operation Sagent Pharmaceuticals have bought a plant in North Carolina from Xellia.

Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.